Poxel Reports First Quarter 2026 Revenue and Provides a Business Update

LYON, France--(BUSINESS WIRE)--Regulatory News: Poxel (Euronext: POXEL - FR0012432516), a clinical-stage biopharmaceutical company developing innovative treatments for severe chronic diseases with metabolic pathophysiology, including metabolic dysfunction-associated steatohepatitis (MASH) and rare metabolic diseases, today announced its revenue for the first quarter ended March 31, 2026, and provided a business update. Commercial and Clinical Activity Update TWYMEEG® (Imeglimin) For the quarter.